Disruptive technology platforms from emerging companies hold great promise for exploiting innovation, but often face legitimacy hurdles due to their liability of newness. Nascent firms must learn new roles with limited precedent, and establish ties with an environment that may not fully understand or value their existence. Using a legitimacy-based lens in the context of the biotechnology industry, we posit a sequential construct - cognitive, regulative, and normative legitimacy - to evaluate emergent technology platforms. Our model of biotechnology platform emergence may provide insights for understanding how breakthroughs achieve legitimacy in the scientific community, mobilize resources and talent, and attain commercial success.
|Original language||English (US)|
|Journal||International Journal of Innovation and Technology Management|
|State||Published - Aug 2013|
All Science Journal Classification (ASJC) codes
- Management of Technology and Innovation